The Cell cycle and Oncology Group was established in 2003. During these years, the group has specialized in using functional genetics tools, as genetically-modified mouse models, genome editing or transcriptomics, as well as biochemical and cellular approaches to answer relevant questions about how cell cycle inhibitors participate in cancer development.

One of the major goals of the lab is to study the roles of cell cycle inhibitors in cancer. During recent years, the group’s work has contributed to discover new functions of cell cycle regulators in angiogenesis (Vidal et al, Proc Natl Acad Sci USA 2005), endochondral bone formation (Yeh et al, Mol Cell Biol 2007), as well as in embryonic (Li et al Cell Stem Cell 2012) and adult stem cell biology (Marques-Torrejon et al Cell Stem Cell 2013; Porlan et al Nature Neuroscience 2013; Vilas et al Oncotarget 2014).

A second goal of the group is to use genetically-modified mouse models to identify new tumor markers and new therapeutic targets (Patent 61/432,316 “Methods for diagnosing Follicular Thyroid Cancer”).

Finally, our group has developed refined mouse models to validate new therapeutic strategies, especially in the field of nanomedicine (Torrecilla et al, Eur. J. Pharm Biopharm 2013; Borrajo et al, J Control Release 2016).